Monoclonal antibody · Immune activation, directed at Programmed cell death protein 1 (PDCD1) · developed by Jiangsu HengRui Medicine Co.
Phase 2/3Most advanced trial
1Registered trials
What is Camrelizumab?
Camrelizumab is a monoclonal antibody that binds the PD-1 receptor on activated T cells, B cells and natural killer cells, blocking its interaction with PD-L1 and PD-L2. This prevents PD-1 signaling and restores cytotoxic T-lymphocyte responses against tumor cells. It is studied in metastatic pancreatic cancer.
Summary written with AI from the sources listed at the end of this page.
At a glance
Also known as
SHR-1210
Drug type
Monoclonal antibody
Targets
Programmed cell death protein 1 (PDCD1), Programmed cell death 1 ligand 1 (CD274) (binding partner it blocks), Programmed cell death 1 ligand 2 (PDCD1LG2) (binding partner it blocks)
Mechanism
Immune activation, directed at Programmed cell death protein 1 (PDCD1)
Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z
This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.